Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aastrom Biosciences Achieves Clinical Milestone in Its Phase I/II U.S. Bone Grafting Trial
-- Safety Endpoint for TRC Product Reached; Trial Expanded --
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, January 31, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call on Friday, February 4, 2005 at 11:00 a.m. (EST). Aastrom's call will begin with brief presentations
View HTML
Toggle Summary Aastrom Biosciences Responds to Recent Article Regarding Contamination of Certain Stem Cell Lines
-- Aastrom Stem Cell Product's Progress on Clinical Pathway Not Impacted --
View HTML
Toggle Summary Aastrom Biosciences Receives Patent Expanding Coverage for Its Single-Pass Perfusion Technology
-- Patent Extends Coverage from Stem Cell Population to Dendritic Cells --
View HTML
Toggle Summary Aastrom Biosciences Concludes October 2002 Common Stock Agreement with Fusion Capital
-- Final $12 Million Tranche Completed at Premium to Market --
View HTML
Toggle Summary Aastrom Biosciences Expands Bone Graft Clinical Trial to Include William Beaumont Hospital in Michigan
-- Enrollment Open for Repair of Severe Leg Fractures Using Company's Proprietary TRCs --
View HTML
Toggle Summary Aastrom Biosciences Announces Appointment of Dr. Gunter Rosskamp as Managing Director of German Subsidiary
Aastrom Biosciences Announces Appointment of Dr. Gunter Rosskamp as Managing Director of German Subsidiary Ann Arbor, Michigan, and Berlin, Germany, December 9, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and Zellera AG (Zellera), its wholly-owned subsidiary, today announced that Gunter
View HTML
Toggle Summary Aastrom Biosciences Issues Correction of Wall Street Journal Article
-- Adult Bone Marrow Stem Cells are Company Focus --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2005 Financial Results
Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2005 Financial Results Ann Arbor, Michigan, November 4 , 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today reported financial results for the first fiscal quarter ended September 30, 2004.  The Company also reported several
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, November 3, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call tomorrow, Thursday, November 4, 2004 at 11:00 a.m. (EST).
View HTML

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.